skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8849

Editorial || FREE PAPER ||

(2135) Views  (391) Full article downloads

Authors: Garry Walsh

Published Date May 2005 Volume 2005:1(1) Pages 1 - 1
DOI: http://dx.doi.org/10.2147/TCRM.S

Garry Walsh

Asthmatic and Allergic Inflammation Group, School of Medicine, University of Aberdeen, UK

Welcome to the first issue of Therapeutics and Clinical Risk Management – a new international peer-reviewed journal. As the title suggests, the journal will publish original research and review articles on the evidence and opinion behind new and existing therapies. A further aim will be to define the usage of these therapies in terms of ultimate uptake and acceptance by the patient and healthcare professional. This is an area that to date has been somewhat neglected, and Dove Medical Press are to be congratulated for the launch of a new title that addresses these vital issues in an era when evidence-based medicine is becoming ever more important. The remit of the journal will of necessity be a broad one and, in this respect, represents a considerable challenge to all involved.








Readers of this article also read:

Medication adherence issues in patients treated for COPD
A review and empirical study of the composite scales of the Das–Naglieri cognitive assessment system
The pathophysiology of bronchiectasis
Moving towards implementation of a clinical ethics consultation program in Egyptian liver transplant units
Ethical issues in kidney transplantation – reflections from Nigeria
Clinical intervention in aging: ethicolegal issues in assessing risk and benefit
Corrigendum: Softec HD hydrophilic acrylic intraocular lens: biocompatibility and precision
When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis
A case of recurrent bloody tears
Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK